Loading clinical trials...
Loading clinical trials...
A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
Conditions
Interventions
Cabozantinib
Placebo
Locations
15
France
Institut Bergonie
Bordeaux, France
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau
Nantes, France
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Academisch Medisch Centrum at University of Amsterdam
Amsterdam, Netherlands
Start Date
February 2, 2015
Primary Completion Date
May 18, 2022
Completion Date
January 15, 2024
Last Updated
August 1, 2025
NCT07467772
NCT01303094
NCT07269535
NCT03493165
NCT05881967
NCT01846520
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions